Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02284386 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty
A Phase 4 study of Pain, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT02284386: Completed Phase 4 study of Pain, sponsored by Pacira Pharmaceuticals.
NCT02284386 is a Phase 4 study of Pain that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 15 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02284386, a Phase 4 study of Pain, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 4, multicenter, open-label study designed to characterize the pharmacokinetic (PK) profile of total bupivacaine in approximately 15 adult subjects undergoing primary unilateral total knee arthroplasty (TKA) with bupivacaine hydrochloride (HCl) spinal nerve block (SNB) and EXPAREL local infiltration into the surgical site.
Conditions Studied
Interventions
- DRUG Bupivacaine SNB
- DRUG EXPAREL Infiltration
Study Locations (2)
Alabama
- Shaols Medical Trials, Inc. - Sheffield
Minnesota
- University of Minnesota Medical Center - Fairview, West Bank - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
What the finished NCT02284386 record still lists
NCT02284386 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine SNB is the first listed.
NCT02284386 reports a single indexed study location in Alabama, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02284386 about?
NCT02284386 is a clinical study titled "Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty". This is a Phase 4, multicenter, open-label study designed to characterize the pharmacokinetic (PK) profile of total bupivacaine in approximately 15 adult subjects undergoing primary unilateral total knee arthroplasty (TKA) with bupivacaine hydrochloride (HCl) spinal nerve block (SNB) and EXPAREL loc...
What is the current status of trial NCT02284386?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2014-12. Estimated completion is 2015-03.
What conditions does trial NCT02284386 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT02284386?
The interventions under investigation include: Bupivacaine SNB (DRUG), EXPAREL Infiltration (DRUG).
Who is sponsoring clinical trial NCT02284386?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02284386 being conducted?
This trial has 2 study locations across Alabama, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02284386's enrollment target sits among peer trials
15 352nd of 374 higher than 21 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Magnesium on Neuromonitoring
RECRUITING · Phase 4
-
Low-Dose Ketamine Infusion During Burn Wound Care
RECRUITING · Phase 4
-
Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery
RECRUITING · Phase 4
-
Optimizing Pain Control in Transurethral Resection of the Prostate
RECRUITING · Phase 4
-
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
RECRUITING · Phase 4
-
Regional Blocks for Lateral Condyle Fractures
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia